Insilico teams up with US firm to build AI models predicting disease decades ahead

Hong Kong-listed Artificial Intelligence drug-discovery company Insilico Medicine has struck a collaboration with US-headquartered Longevity" class="entity-link entity-organization" data-entity-id="134776" data-entity-type="organization">Human Longevity to co-develop what they describe as “the industry’s first large-scale” AI foundation models capable of predicting diseases – such as cancer – decades before clinical symptoms appear.The partnership was announced as the global Longevity market, fuelled by an ageing population and rising consumption demand, was valued at about US$5.3 trillion and projected to reach US$8 trillion by 2030, according to a recent UBS report.Insilico founder and CEO Alex Zhavoronkov, in a written reply, framed the tie-up as the world’s two leading companies in the AI and Longevity fields joining forces, adding they “have developed a conceptually new type of personal Longevity AI that will not only let you live longer, but also help you and others discover new Longevity drugs that work for everyone.”